Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV

被引:13
|
作者
Milic, Jovana [1 ,2 ]
Menozzi, Valentina [3 ]
Schepis, Filippo [4 ]
Malagoli, Andrea [1 ]
Besutti, Giulia [2 ]
Franconi, Iacopo [1 ]
Raimondi, Alessandro [1 ]
Carli, Federica [1 ]
Mussini, Cristina [1 ]
Sebastiani, Giada [5 ]
Guaraldi, Giovanni [1 ]
机构
[1] Univ Modena & Reggio Emilia, Modena HIV Metab Clin, Modena, Italy
[2] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy
[3] Univ Modena & Reggio Emilia, Modena, Italy
[4] Univ Modena & Reggio Emilia, Dept Gastroenterol, Modena, Italy
[5] McGill Univ, Dept Med, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
frailty; HIV; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; METABOLIC SYNDROME; STEATOHEPATITIS; MANAGEMENT; DIAGNOSIS; OBESITY; NAFLD;
D O I
10.1097/QAD.0000000000002650
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH). Design: This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018-2019. Methods: Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP >= 248 dB/m), while significant liver fibrosis or cirrhosis (stage >= F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates. Results: We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4(+) cell count 700 cells/mu l, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6-15], vitamin D insufficiency (OR = 1.94, 1.2-3.2), obesity (OR = 8.1, 4.4-14.6), diabetes (OR = 3.2, 1.9-5.6), metabolic syndrome (OR = 2.41, 1.47-3.95) and osteoporosis (OR = 0.37, 0.16-0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3-3.5), fibrosis (OR = 2, 1-3.7), NAFLD with fibrosis (OR = 9.2, 5.2-16.8), diabetes (OR = 1.7, 1-2.7) and multimorbidity (OR = 2.5, 1.5-4). Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH. Copyright (C) 2020 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1915 / 1921
页数:7
相关论文
共 50 条
  • [41] Improvement of liver steatosis achieved byprobiotics in patients with nonalcoholic fatty liver disease
    Copaci, I.
    Franculescu, A.
    Micu, L.
    Chiriac, G.
    Mihaila, M.
    Iliescu, E. L.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S585 - S585
  • [42] Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease
    Soon, Gwyneth Shook Ting
    Wee, Aileen
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2021, 64 (05) : 104 - 111
  • [43] Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV
    Lake, Jordan E.
    Taron, Jana
    Ribaudo, Heather J.
    Leon-Cruz, Jorge
    Utay, Netanya S.
    Swaminathan, Shobha
    Fitch, Kathleen V.
    Kileel, Emma M.
    Paradis, Kayla
    Fulda, Evelynne S.
    Ho, Ken S.
    Luetkemeyer, Anne F.
    Johnston, Carrie D.
    Zanni, Markella V.
    Douglas, Pamela S.
    Grinspoon, Steven K.
    Lu, Michael T.
    Fichtenbaum, Carl J.
    AIDS, 2023, 37 (14) : 2149 - 2159
  • [44] Nonalcoholic fatty liver disease and HIV infection
    Merriman R.B.
    Current HIV/AIDS Reports, 2006, 3 (3) : 113 - 117
  • [45] Nonalcoholic Fatty Liver Disease and HIV Infection
    Vallet-Pichard, Anais
    Mallet, Vincent
    Pol, Stanislas
    SEMINARS IN LIVER DISEASE, 2012, 32 (02) : 158 - 166
  • [46] Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Amjad, Waseem
    Shalaurova, Irina
    Garcia, Erwin
    Gruppen, Eke G.
    Dullaart, Robin P. F.
    DePaoli, Alex M.
    Jiang, Z. Gordon
    Lai, Michelle
    Connelly, Margery A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [47] THE RELATIONSHIP BETWEEN SERUM ACID SPHINOLIPASE AND THE DEGREE OF STEATOSIS AND FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE
    Chang, Jiabao
    Fu, Xiling
    Li, Jinlong
    Yin, Yin
    Hu, Yueshuang
    Yang, Mongyin
    ACTA MEDICA MEDITERRANEA, 2020, 36 (03): : 1633 - 1638
  • [48] Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease
    Abrams, GA
    Kunde, SS
    Lazenby, AJ
    Clements, RH
    HEPATOLOGY, 2004, 40 (02) : 475 - 483
  • [49] Reply to: "Hepatic fibrosis - and not steatosis - is the main determinant of arterial stiffness in nonalcoholic fatty liver disease"
    Styczynski, Grzegorz
    Kalinowski, Piotr
    Michalowski, Lukasz
    Paluszkiewicz, Rafal
    Ziarkiewicz-Wroblewska, Bogna
    Zieniewicz, Krzysztof
    Tataj, Emanuel
    Szmigielski, Cezary
    Jedrusik, Piotr
    ATHEROSCLEROSIS, 2019, 290 : 224 - 225
  • [50] Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease Reply
    Lefere, Sander
    Geerts, Anja
    De Bruyne, Ruth
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (10) : 2698 - 2699